Liu Ke-Jun, Wu Hai-Ying
State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Department of Medical Oncology, Dongguan People's Hospital, Dongguan, China.
Oncotarget. 2015 Sep 8;6(26):22750-7. doi: 10.18632/oncotarget.4262.
Patients with non-small-cell lung cancer (NSCLC) often have an advanced disease when firstly diagnosed. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR). In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. Results showed that the objective response rate(ORR) of this novel regimen is 43%, median progression-free survival (PFS) was 5.2 months (95% CI, 3.7 to 6.7 months) and median overall survival (OS) was 11.4 months (95% CI, 8.8 to 13.9 months). Adverse events were generally mild, ranging from grade 1 to grade 3. In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. Randomized clinical trials are needed to further investigate the efficacy of this regimen.
非小细胞肺癌（NSCLC）患者初诊时往往已处于疾病晚期。贝伐单抗是一种抗血管内皮生长因子受体（VEGFR）的单克隆抗体。在本研究中，我们回顾性分析了顺铂、培美曲塞和贝伐单抗用于既往治疗过的晚期NSCLC的疗效。结果显示，这一新方案的客观缓解率（ORR）为43%，中位无进展生存期（PFS）为5.2个月（95%CI，3.7至6.7个月），中位总生存期（OS）为11.4个月（95%CI，8.8至13.9个月）。不良事件一般较轻，从1级到3级。总之，顺铂、培美曲塞和贝伐单抗联合用药在部分NSCLC患者中取得了有前景的结果。需要进行随机临床试验以进一步研究该方案的疗效。
